J&J's Janssen unit is recalling one lot of Ortho-Cept tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.
Many pharma companies create DTC efforts around a branded product, but plenty of drugmakers go the disease education route, too. So when is the right time to use each? That all depends on the population a pharma is trying to reach, and as Pfizer found recently, sometimes they can be used simultaneously to get targeted messages across to different patient groups.
A federal lawsuit has put an over-the-counter drug packaging practice in the spotlight by trying to extract a penalty from Pfizer for using "nonfunctional slack-fill."
Two years after going down in flames in a Phase III study for CD22-positive non-Hodgkin's lymphoma, Pfizer has helped resurrect hopes for top drug prospect inotuzumab ozogamicin, saying the drug hit its first primary endpoint for spurring hematologic remission in patients with CD22-positive acute lymphoblastic leukemia.
Pfizer racked up an important win in the first trial over Zoloft's alleged links to birth defects. A St. Louis jury decided on Friday that the drug giant isn't liable for congenital abnormalities in a boy whose mother took Zoloft during her pregnancy.
The U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences, whose hep C drugs vaulted it to the top, according to PMLiVE based on sales info from GlobalData.
Pfizer reported today that it had cut short a Phase III study of palbociclib, recently approved under an accelerated pathway as Ibrance, after clearly demonstrating that it had met its primary endpoint: progression-free survival with a combination of Ibrance plus fulvestrant in women with hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer.
Pfizer won accelerated approval of Ibrance as a first-line breast cancer treatment in February. Now it says that data in a study of the drug as a second-line treatment was so good that it stopped that study early.
It's no secret that technology is transforming healthcare. But Big Pharma? Not quite yet. Some risk-averse drugmakers have been slow to adopt the digital lifestyle.
Japan's RegImmune has joined with Pfizer and the former Juvenile Diabetes Research Foundation in a partnership to collaborate on research for an antigen-specific preventative for Type 1 diabetes. Financial arrangements were not disclosed, but Pfizer is to provide finances and expertise.